1236. Baseline liver stiffness and alanine transaminase predicts reduction in liver stiffness in people with chronic hepatitis B on tenofovir alafenamide

BACKGROUND: Globally, 296 million people are infected with chronic hepatitis B (CHB) and at risk for cirrhosis and hepatocellular carcinoma. Suppressive therapy with a nucleos(t)ide analogue (NUC) such as tenofovir alafenamide (TAF) reduces risk of cirrhosis and cancer. Transient elastography measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lydia, George, Nivya, Price, Angie, Kottilil, Shyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752225/
http://dx.doi.org/10.1093/ofid/ofac492.1068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752225/
http://dx.doi.org/10.1093/ofid/ofac492.1068

Ejemplares similares